ArticleCancer science2025
Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study.
Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Trastuzumab Deruxtecan-Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence.Cancer control : journal of the Moffitt Cancer CenterPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating data demonstrate the robust overall and intracranial activity of trastuzumab deruxtecan (T-DXd) in HER2-positive breast cancer brain metastasis (BCBM). Limited data are available on HER2-low/zero BCBM, as well as patients with symptomatic active BM, leptomeningeal disease (LMD), and poor performance status. This multicenter, retrospective, real-world study enrolled patients diagnosed with HER2-positive or low/zero BCBM receiving T-DXd. Progression-free survival (PFS), intracranial progression-free survival (IC-PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), IC-ORR, IC-DCR, and adverse events (AEs) were evaluated. From January 2020 to July 2024, 58 HER2-positive and 30 HER2-low/zero patients were enrolled. In the HER2-positive cohort, the median PFS, IC-PFS, and OS were 11, 13, and 46 months, respectively. ORR and DCR were 65.2% and 91.3% systemically, with IC-ORR and IC-DCR of 61.0%/90.2% (RECIST 1.1) and 59.5%/88.1% (RANO-BM). In the HER2-low/zero cohort, median PFS, IC-PFS, and OS were 4, 5, and 26 months. ORR and DCR were 33.3% and 66.7%. IC-ORR and IC-DCR were 44.4% and 88.9% by RECIST 1.1 and RANO-BM. HR+/HER2-low patients had significantly longer PFS than HR-/HER2-low (10 vs. 3 months, p < 0.001). In the LMD cohort, the 12-month IC-PFS rates were 67.7% and 60.0% in HER2-positive and low/zero cohorts. The most common AEs included fatigue (45.9%) and appetite loss (25.2%). Seven (8.0%) patients suffered interstitial lung disease (ILD), including 2 (2.3%) grade 3. T-DXd showed substantial and durable overall and intracranial efficacy in HER2-positive and low/zero BCBM, including challenging subgroups with active BM or LMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.